RTTNews | Feb 12, 2021 09:49AM EST

09:48 Friday, February 12, 2021 (RTTNews.com) - Shares of NantKwest Inc. (NK) are rising over 7% Friday morning, following FDA clearance for the expansion of the active Phase 1 COVID-19 vaccine trial and a second trial to test a novel combination of T-cell-based hAd5 subcutaneous prime vaccine with a room-temperature oral or sublingual boost, to induce T-Cell, mucosal, and antibody immunity.

The oral trial is a new study and the sublingual trial is the cohort C expansion to the Phase 1 subcutaneous trial, which was initiated last Fall. Both oral and sublingual trials are anticipated to begin this month and will be conducted at two sites in California.

The stock, which has been trading between $2.52 and $29.59 for the past one year, is currently trading at $29.00, up $2.96 or 11.37%.

Read the original article on RTTNews ( https://www.rttnews.com/3169472/stock-alert-nantkwest-shares-up-11.aspx)

For comments and feedback: contact editorial@rttnews.com

Copyright(c) 2021 RTTNews.com All Rights Reserved